US009750785B2

(12) **United States Patent**
Kenney et al.

(10) **Patent No.: US 9,750,785 B2**
(45) **Date of Patent: *Sep. 5, 2017**

(54) **VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION**

(71) Applicant: **Par Pharmaceutical, Inc.**, Chestnut Ridge, NY (US)

(72) Inventors: **Matthew Kenney**, New Haven, MI (US); **Vinayagam Kannan**, Rochester, MI (US); **Sunil Vandse**, Basking Ridge, NJ (US); **Suketu Sanghvi**, Kendall Park, NJ (US)

(73) Assignee: **PAR PHARMACEUTICAL, INC.**, Chestnut Ridge, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/426,703**

(22) Filed: **Feb. 7, 2017**

(65) **Prior Publication Data**

US 2017/0157203 A1 Jun. 8, 2017

Related U.S. Application Data

(63) Continuation-in-part of application No. 15/289,640, filed on Oct. 10, 2016, which is a continuation-in-part of application No. 14/717,877, filed on May 20, 2015, which is a continuation of application No. 14/610,499, filed on Jan. 30, 2015, now abandoned.

(51) **Int. Cl.**

A61K 38/11	(2006.01)
A61K 47/12	(2006.01)
G01N 30/74	(2006.01)
G01N 30/88	(2006.01)
G01N 30/02	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/11*** (2013.01); ***A61K 47/12*** (2013.01); ***G01N 30/74*** (2013.01); ***G01N 30/88*** (2013.01); *G01N 2030/027* (2013.01); *G01N 2030/8831* (2013.01)

(58) **Field of Classification Search**

CPC A61K 38/11; C07K 7/16

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,542,124	A	9/1985	Huffman et al.
4,604,378	A	8/1986	Callahan et al.
4,684,622	A	8/1987	Ali et al.
4,746,508	A	5/1988	Carey et al.
4,762,820	A	8/1988	Gavras
4,764,378	A	8/1988	Keith et al.
4,781,871	A	11/1988	West, III et al.
5,042,975	A	8/1991	Chien et al.
5,124,315	A	6/1992	Ceschel et al.
5,192,741	A	3/1993	Orsolini et al.
5,204,112	A	4/1993	Hope et al.
5,225,212	A	7/1993	Martin et al.
5,250,022	A	10/1993	Chien et al.
5,252,263	A	10/1993	Hope et al.
5,288,497	A	2/1994	Stanley et al.
5,288,498	A	2/1994	Stanley et al.
5,359,030	A	10/1994	Ekwuribe
5,424,068	A	6/1995	Filip
5,482,931	A	1/1996	Harris et al.
5,698,516	A	12/1997	Nilsson et al.
5,702,717	A	12/1997	Cha et al.
5,770,559	A	6/1998	Manning et al.
5,776,885	A	7/1998	Orsolini et al.
5,785,989	A	7/1998	Stanley et al.
5,811,399	A	9/1998	Khavinson et al.
5,889,110	A	3/1999	Hutchinson
5,902,790	A	5/1999	Green et al.
5,972,894	A	10/1999	Sinackevich et al.
5,981,474	A	11/1999	Manning et al.
5,989,857	A	11/1999	Mundschenk
6,004,573	A	12/1999	Rathi et al.
6,034,175	A	3/2000	Hutchinson
6,086,918	A	7/2000	Stern et al.
6,117,949	A	9/2000	Rathi et al.
6,143,722	A	11/2000	Melin et al.
6,174,547	B1	1/2001	Dong et al.
6,180,608	B1	1/2001	Gefter et al.
6,187,756	B1	2/2001	Lee et al.
6,201,072	B1	3/2001	Rathi et al.
6,264,981	B1	7/2001	Zhang et al.
6,287,588	B1	9/2001	Shih et al.
6,589,549	B2	7/2003	Shih et al.
6,592,894	B1	7/2003	Zarif et al.
6,630,486	B1	10/2003	Royer
6,720,001	B2	4/2004	Chen et al.

(Continued)

OTHER PUBLICATIONS

Label for Vasostrict (vasopressin injection) for intravenous use, downloaded from www.fda.gov on Mar. 21, 2017.*

AHFS Drug Information. Vasopressin. Pituitary. 2011; 68:28, 3261-3263.

Alten, et al. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. Pediatr Crit Care Med. May 2012;13(3):300-4. doi: 10.1097/PCC.0b013e31822f1753.

Angus, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. Jul. 2001;29(7):1303-10.

(Continued)

Primary Examiner — Christina Bradley

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

11 Claims, 19 Drawing Sheets